These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8072531)

  • 1. India moves gently to liberalize drug industry.
    Jayaraman KS
    Nature; 1994 Sep; 371(6492):8. PubMed ID: 8072531
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating the pharmaceutical industry: who really benefits?
    Stano M
    Am J Manag Care; 2000 Jan; 6(1):29-31. PubMed ID: 11009744
    [No Abstract]   [Full Text] [Related]  

  • 3. New pharma-biotech company formation in India.
    Saberwal G
    Nat Biotechnol; 2006 May; 24(5):499-501. PubMed ID: 16680124
    [No Abstract]   [Full Text] [Related]  

  • 4. Controlling the cost of prescription drugs.
    White JR
    Health Prog; 1992 Mar; 73(2):12-4, 25. PubMed ID: 10116498
    [No Abstract]   [Full Text] [Related]  

  • 5. The GATT TRIPS agreement and health care in India.
    Otten A
    Ceylon Med J; 1995 Sep; 40(3):91-3. PubMed ID: 8536333
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescription drug manufacturers get warning on prices.
    Margolis RE
    Healthspan; 1993 Mar; 10(3):19-20. PubMed ID: 10125344
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmaceutical industry--to whom is it accountable?
    Holmer AF
    N Engl J Med; 2000 Nov; 343(19):1415; discussion 1417. PubMed ID: 11183877
    [No Abstract]   [Full Text] [Related]  

  • 8. Revised drug policy.
    Shelat AJ
    J Indian Med Assoc; 1995 Mar; 93(3):117-8. PubMed ID: 8522818
    [No Abstract]   [Full Text] [Related]  

  • 9. [Novartis should discontinue its patent case in India!].
    PehrOlov P
    Lakartidningen; 2007 Feb 14-20; 104(7):524. PubMed ID: 17375688
    [No Abstract]   [Full Text] [Related]  

  • 10. Firms discovering reality of clinical research in India.
    Jayaraman KS
    Nat Rev Drug Discov; 2006 Jan; 5(1):6. PubMed ID: 16485338
    [No Abstract]   [Full Text] [Related]  

  • 11. Just roiling along.
    Tieman J
    Mod Healthc; 2000 Oct; 30(44):8-9. PubMed ID: 11141844
    [No Abstract]   [Full Text] [Related]  

  • 12. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinton's breakthrough drug committee: will it stifle new drug development?
    Gatty B
    Hosp Formul; 1993 Nov; 28(11):946, 945. PubMed ID: 10130236
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies renew price-curb talk.
    Weissenstein E
    Mod Healthc; 1994 Feb; 24(6):17. PubMed ID: 10131519
    [No Abstract]   [Full Text] [Related]  

  • 15. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 16. New patent rules drive Indian drug firms to research.
    Jayaraman KS
    Nat Med; 2005 Jan; 11(1):3. PubMed ID: 15635420
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical policy in Italy: Theory, politics and practice.
    Garattini L; Cornago D
    Eur J Health Econ; 2006 Jun; 7(2):89-90. PubMed ID: 16688431
    [No Abstract]   [Full Text] [Related]  

  • 18. Pryor bill to enter fray over drug costs.
    Weissenstein E
    Mod Healthc; 1992 Mar; 22(9):26. PubMed ID: 10116351
    [No Abstract]   [Full Text] [Related]  

  • 19. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 20. These doctor's mission: keeping drug costs down.
    Guglielmo WJ
    Med Econ; 2001 Apr; 78(8):108-10, 113-6. PubMed ID: 11386066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.